81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology

Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in dia...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1
Hauptverfasser:	CAUSSY, CYRIELLE, VERGÈS, BRUNO, LELEU, DAMIEN, DUVILLARD, LAURENCE, ABICHOU-KLICH, AMNA, SEGRESTIN, BERENICE, BIN, SYLVIE, ROULAND, ALEXIA, DELAUNAY, DOMINIQUE, HADJADJ, SAMY, PRIMOT, CLAIRE, PETIT, JEAN-MICHEL, CHARRIÈRE, SYBIL, MOULIN, PHILIPPE, LEVRERO, MASSIMO, CARIOU, BERTRAND, DISSE, EMMANUEL
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes mellitus Fibrosis Hepatology Liver diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in diabetology. Methods: Interim analysis from a multicenter prospective study including 568 patients with T2D and MASLD, age 40-80 years, BMI
ISSN:	0012-1797 1939-327X
DOI:	10.2337/db24-81-OR